- •Preface and Acknowledgments
- •Contents
- •Contributors
- •1: Embryology for Urologists
- •Introduction
- •Renal Development
- •Pronephros
- •Mesonephros
- •Metanephros
- •Development of the Collecting System
- •Critical Steps in Further Development
- •Anomalies of the Kidney
- •Renal Agenesis
- •Renal Aplasia
- •Renal Hypoplasia
- •Renal Ectopia
- •Renal Fusion
- •Ureteral Development
- •Anomalies of Origin
- •Anomalies of Number
- •Incomplete Ureteral Duplication
- •Complete Ureteral Duplication
- •Ureteral Ectopia
- •Embryology of Ectopia
- •Clinical Correlation
- •Location of Ectopic Ureteral Orifices – Male (in Descending Order According to Incidence)
- •Symptoms
- •Ureteroceles
- •Congenital Ureteral Obstruction
- •Pipestem Ureter
- •Megaureter-Megacystis Syndrome
- •Prune Belly Syndrome
- •Vascular Ureteral Obstructions
- •Division of the Urogenital Sinus
- •Bladder Development
- •Urachal Anomalies
- •Cloacal Duct Anomalies
- •Other Bladder Anomalies
- •Bladder Diverticula
- •Bladder Extrophy
- •Gonadal Development
- •Testicular Differentiation
- •Ovarian Differentiation
- •Gonadal Anomalies
- •Genital Duct System
- •Disorders of Testicular Function
- •Female Ductal Development
- •Prostatic Urethral Valves
- •Gonadal Duct Anomalies
- •External Genital Development
- •Male External Genital Development
- •Female External Genital Development
- •Anomalies of the External Genitalia
- •References
- •2: Gross and Laparoscopic Anatomy of the Upper Urinary Tract and Retroperitoneum
- •Overview
- •The Kidneys
- •The Renal Vasculature
- •The Renal Collecting System
- •The Ureters
- •Retroperitoneal Lymphatics
- •Retroperitoneal Nerves
- •The Adrenal Glands
- •References
- •3: Gross and Laparoscopic Anatomy of the Lower Urinary Tract and Pelvis
- •Introduction
- •Female Pelvis
- •Male Pelvis
- •Pelvic Floor
- •Urinary Bladder
- •Urethra
- •Male Urethra
- •Female Urethra
- •Sphincter Mechanisms
- •The Bladder Neck Component
- •The Urethral Wall Component
- •The External Urethral Sphincter
- •Summary
- •References
- •4: Anatomy of the Male Reproductive System
- •Testis and Scrotum
- •Spermatogenesis
- •Hormonal Regulation of Spermatogenesis
- •Genetic Regulation of Spermatogenesis
- •Epididymis and Ductus Deferens
- •Accessory Sex Glands
- •Prostate
- •Seminal Vesicles
- •Bulbourethral Glands
- •Penis
- •Erection and Ejaculation
- •References
- •5: Imaging of the Upper Tracts
- •Anatomy of the Upper Tracts and Introduction to Imaging Modalities
- •Introduction
- •Renal Upper Tract Basic Anatomy
- •Modalities Used for Imaging the Upper Tracts
- •Ultrasound
- •Radiation Issues
- •Contrast Issues
- •Renal and Upper Tract Tumors
- •Benign Renal Tumors
- •Transitional Cell Carcinoma
- •Renal Mass Biopsy
- •Renal Stone Disease
- •Ultrasound
- •Plain Radiographs and IVU
- •Renal Cystic Disease
- •Benign Renal Cysts
- •Hereditary Renal Cystic Disease
- •Complex Renal Cysts
- •Renal Trauma
- •References
- •Introduction
- •Pathophysiology
- •Susceptibility and Resistance
- •Epidemiological Breakpoints
- •Clinical Breakpoints
- •Pharmacodynamic Parameters
- •Pharmacokinetic Parameters
- •Fosfomycin
- •Nitrofurantoin
- •Pivmecillinam
- •b-Lactam-Antibiotics
- •Penicillins
- •Cephalosporins
- •Carbapenems
- •Aminoglycosides
- •Fluoroquinolones
- •Trimethoprim, Cotrimoxazole
- •Glycopeptides
- •Linezolid
- •Conclusion
- •References
- •7: An Overview of Renal Physiology
- •Introduction
- •Body Fluid Compartments
- •Regulation of Potassium Balance
- •Regulation of Acid–Base Balance
- •Diuretics
- •Suggested Reading
- •8: Ureteral Physiology and Pharmacology
- •Ureteral Anatomy
- •Modulation of Peristalsis
- •Ureteral Pharmacology
- •Conclusion
- •References
- •Introduction
- •Afferent Signaling Pathways
- •Efferent Signaling
- •Parasympathetic Nerves
- •Sympathetic Nerves
- •Vesico-Spinal-Vesical Micturition Reflex
- •Peripheral Targets
- •Afferent Signaling Mechanisms
- •Urothelium
- •Myocytes
- •Cholinergic Receptors
- •Muscarinic Receptors
- •Nicotinic Receptors
- •Adrenergic Receptors (ARs)
- •a-Adrenoceptors
- •b-Adrenoceptors
- •Transient Receptor Potential (TRP) Receptors
- •Phosphodiesterases (PDEs)
- •CNS Targets
- •Opioid Receptors
- •Serotonin (5-HT) Mechanisms
- •g-Amino Butyric Acid (GABA) Mechanisms
- •Gabapentin
- •Neurokinin and Neurokinin Receptors
- •Summary
- •References
- •10: Pharmacology of Sexual Function
- •Introduction
- •Sexual Desire/Arousal
- •Endocrinology
- •Steroids in the Male
- •Steroids in the Female
- •Neurohormones
- •Neurotransmitters
- •Dopamine
- •Serotonin
- •Pharmacological Strategies
- •CNS Drugs
- •Enzyme-inducing Antiepileptic Drugs
- •Erectile Function
- •Ejaculatory Function
- •Premature Ejaculation
- •Abnormal Ejaculation
- •Conclusions
- •References
- •Epidemiology
- •Calcium-Based Urolithiasis
- •Uric Acid Urolithiasis
- •Infectious Urolithiasis
- •Cystine-Based Urolithiasis
- •Aims
- •Who Deserves Metabolic Evaluation?
- •Metabolic Workup for Stone Producers
- •Medical History and Physical Examination
- •Stone Analysis
- •Serum Chemistry
- •Urine Evaluation
- •Urine Cultures
- •Urinalysis
- •Twenty-Four Hour Urine Collections
- •Radiologic Imaging
- •Medical Management
- •Conservative Management
- •Increased Fluid Intake
- •Citrus Juices
- •Dietary Restrictions
- •Restricted Oxalate Diet
- •Conservative Measures
- •Selective Medical Therapy
- •Absorptive Hypercalciuria
- •Thiazide
- •Orthophosphate
- •Renal Hypercalciuria
- •Primary Hyperparathyroidism
- •Hyperuricosuric Calcium Oxalate Nephrolithiasis
- •Enteric Hyperoxaluria
- •Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Distal Renal Tubular Acidosis
- •Chronic Diarrheal States
- •Thiazide-Induced Hypocitraturia
- •Idiopathic Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Hypomagnesiuric Calcium Nephrolithiasis
- •Gouty Diathesis
- •Cystinuria
- •Infection Lithiasis
- •Summary
- •References
- •12: Molecular Biology for Urologists
- •Introduction
- •Inherited Changes in Cancer Cells
- •VEGR and Cell Signaling
- •Targeting mTOR
- •Conclusion
- •References
- •13: Chemotherapeutic Agents for Urologic Oncology
- •Introduction
- •Bladder Cancer
- •Muscle Invasive Bladder Cancer
- •Metastatic Bladder Cancer
- •Conclusion
- •Prostate Cancer
- •Other Chemotherapeutic Drugs or Combinations for Treating HRPC
- •Conclusion
- •Renal Cell Carcinoma
- •Chemotherapy
- •Immunotherapy
- •Angiogenesis Inhibitor Drugs
- •Conclusion
- •Testicular Cancer
- •Stage I Seminoma
- •Stage I non-seminomatous Germ Cell Tumours (NSGCT)
- •Metastatic Germ Cell Tumours
- •Low-Volume Metastatic Disease (Stage II A/B)
- •Advanced Metastatic Disease
- •Salvage Chemotherapy for Relapsed or Refractory Disease
- •Conclusion
- •Penile Cancer
- •Side Effects of Chemotherapy
- •Conclusion
- •References
- •14: Tumor and Transplant Immunology
- •Antibodies
- •Cytotoxic and T-helper Cells
- •Immunosuppression
- •Induction Therapy
- •Maintenance Therapy
- •Rejection
- •Posttransplant Lymphoproliferative Disease
- •Summary
- •References
- •15: Pathophysiology of Renal Obstruction
- •Causes of Renal Obstruction
- •Effects on Prenatal Development
- •Prenatal Hydronephrosis
- •Spectrum of Renal Abnormalities
- •Renal Functional Changes
- •Renal Growth/Counterbalance
- •Vascular Changes
- •Inflammatory Mediators
- •Glomerular Development Changes
- •Mechanical Stretch of Renal Tubules
- •Unilateral Versus Bilateral
- •Limitations of Animal Models
- •Future Research
- •Issues in Patient Management
- •Diagnostic Imaging
- •Ultrasound
- •Intravenous Urography
- •Antegrade Urography and the Whitaker Test
- •Nuclear Renography
- •Computed Tomography
- •Magnetic Resonance Urography
- •Hypertension
- •Postobstructive Diuresis
- •References
- •Introduction
- •The Normal Lower Urinary Tract
- •Anatomy
- •Storage Function
- •Voiding Function
- •Neural Control
- •Symptoms
- •Flow Rate and Post-void Residual
- •Voiding Cystometry
- •Male
- •Female
- •Neurourology
- •Conclusions
- •References
- •17: Urologic Endocrinology
- •The Testis
- •Normal Androgen Metabolism
- •Epidemiological Aspects
- •Prostate
- •Brain
- •Muscle Mass and Adipose Tissue
- •Bones
- •Ematopoiesis
- •Metabolism
- •Cardiovascular System
- •Clinical Assessment
- •Biochemical Assessment
- •Treatment Modalities
- •Oral Preparations
- •Parenteral Preparations
- •Transdermal Preparations
- •Side Effects and Treatment Monitoring
- •Body Composition
- •Cognitive Decline
- •Bone Metabolism
- •The Kidneys
- •Endocrine Functions of the Kidney
- •Erythropoietin
- •Calcitriol
- •Renin
- •Paraneoplastic Syndromes
- •Hypercalcemia
- •Hypertension
- •Polycythemia
- •Other Endocrine Abnormalities
- •References
- •General Physiology
- •Prostate Innervation
- •Summary
- •References
- •Wound Healing
- •Inflammation
- •Proliferation
- •Remodeling
- •Principles of Plastic Surgery
- •Tissue Characteristics
- •Grafts
- •Flap
- •References
- •Lower Urinary Tract Symptoms
- •Storage Phase
- •Voiding Phase
- •Return to Storage Phase
- •Urodynamic Parameters
- •Urodynamic Techniques
- •Volume Voided Charts
- •Pad Testing
- •Typical Test Schedule
- •Uroflowmetry
- •Post Voiding Residual
- •Further Diagnostic Evaluation of Patients
- •Cystometry with or Without Video
- •Cystometry
- •Videocystometrography (Cystometry + Cystourethrography)
- •Cystometric Findings
- •Comment:
- •Measurements During the Storage Phase:
- •Measurements During the Voiding Phase:
- •Abnormal Function
- •Disorders of Sensation
- •Causes of Hypersensitive Bladder Sensation
- •Causes of Hyposensitive Bladder Sensation
- •Disorders of Detrusor Motor Function
- •Bladder Outflow Tract Dysfunction
- •Detrusor–Urethral Dyssynergia
- •Detrusor–Bladder Neck Dyssynergia
- •Detrusor–Sphincter Dyssynergia
- •Complex Urodynamic Investigation
- •Urethral Pressure Measurement
- •Technique
- •Neurophysiological Evaluation
- •Conclusion
- •References
- •Endoscopy
- •Cystourethroscopy
- •Ureteroscopy and Ureteropyeloscopy
- •Nephroscopy
- •Virtual Reality Simulators
- •Lasers
- •Clinical Application of Lasers
- •Condylomata Acuminata
- •Urolithiasis
- •Benign Prostatic Hyperplasia
- •Ureteral and Urethral Strictures
- •Conclusion
- •References
- •Introduction
- •The Prostatitis Syndromes
- •The Scope of the Problem
- •Category III CP/CPPS
- •The Goal of Treatment
- •Conservative Management
- •Drug Therapy
- •Antibiotics
- •Anti-inflammatories
- •Alpha blockers
- •Hormone Therapies
- •Phytotherapies
- •Analgesics, muscle relaxants and neuromodulators
- •Surgery
- •A Practical Management Plan
- •References
- •Orchitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment of Infectious Orchitis
- •Epididymitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation of Epididymitis
- •Treatment of Acute Epididymitis
- •Treatment of Chronic Epididymitis
- •Treatment of Spermatic Cord Torsion
- •Fournier’s Gangrene
- •Definition and Etiology
- •Risk Factors
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment
- •References
- •Fungal Infections
- •Candidiasis
- •Aspergillosis
- •Cryptococcosis
- •Blastomycosis
- •Coccidioidomycosis
- •Histoplasmosis
- •Radiographic Findings
- •Treatment
- •Tuberculosis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Schistosomiasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Filariasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Onchocerciasis
- •References
- •25: Sexually Transmitted Infections
- •Introduction
- •STIs Associated with Genital Ulcers
- •Herpes Simplex Virus
- •Diagnosis
- •Treatment
- •Chancroid
- •Diagnosis
- •Treatment
- •Syphilis
- •Diagnosis
- •Treatment
- •Lymphogranuloma Venereum
- •Diagnosis
- •Treatment
- •Chlamydia
- •Diagnosis
- •Treatment
- •Gonorrhea
- •Diagnosis
- •Treatment
- •Trichomoniasis
- •Diagnosis
- •Treatment
- •Human Papilloma Virus
- •Diagnosis
- •Treatment
- •Scabies
- •Diagnosis
- •Treatment
- •References
- •26: Hematuria: Evaluation and Management
- •Introduction
- •Classification of Hematuria
- •Macroscopic Hematuria
- •Microscopic Hematuria
- •Dipstick Hematuria
- •Pseudohematuria
- •Factitious Hematuria
- •Menstruation
- •Aetiology
- •Malignancy
- •Urinary Calculi
- •Infection and Inflammation
- •Benign Prostatic Hyperplasia
- •Trauma
- •Drugs
- •Nephrological Causes
- •Assessment
- •History
- •Examination
- •Investigations
- •Dipstick Urinalysis
- •Cytology
- •Molecular Tests
- •Blood Tests
- •Flexible Cystoscopy
- •Upper Urinary Tract Evaluation
- •Renal USS
- •KUB Abdominal X-Ray
- •Intravenous Urography (IVU)
- •Computed Tomography (CT)
- •Retrograde Urogram Studies
- •Magnetic Resonance Imaging (MRI)
- •Additional Tests and Renal Biopsy
- •Intractable Hematuria
- •Loin Pain Hematuria Syndrome
- •References
- •27: Benign Prostatic Hyperplasia (BPH)
- •Historical Background
- •Pathophysiology
- •Patient Assessment
- •Treatment of BPH
- •Watchful Waiting
- •Drug Therapy
- •Interventional Therapies
- •Conclusions
- •References
- •28: Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease
- •Erectile Dysfunction
- •Introduction
- •Diagnosis
- •Basic Evaluation
- •Cardiovascular System and Sexual Activity
- •Optional Tests
- •Treatment
- •Medical Treatment
- •Oral Agents
- •Phosphodiesterase Type 5 (PDE 5) Inhibitors
- •Nonresponders to PDE5 Inhibitors
- •Apomorphine SL
- •Yohimbine
- •Intracavernosal and Intraurethral Therapy
- •Intracavernosal Injection (ICI) Therapy
- •Intraurethral Therapy
- •Vacuum Constriction Devices
- •Surgical Therapy
- •Conclusion
- •Peyronie´s Disease (PD)
- •Introduction
- •Oral Drug Therapy
- •Intralesional Drug Therapy
- •Iontophoresis
- •Radiation Therapy
- •Surgical Therapy
- •References
- •29: Premature Ejaculation
- •Introduction
- •Epidemiology
- •Defining Premature Ejaculation
- •Voluntary Control
- •Sexual Satisfaction
- •Distress
- •Psychosexual Counseling
- •Pharmacological Treatment
- •On-Demand Treatment with Tramadol
- •Topical Anesthetics
- •Phosphodiesterase Inhibitors
- •Surgery
- •Conclusion
- •References
- •30: The Role of Interventional Management for Urinary Tract Calculi
- •Contraindications to ESWL
- •Complications of ESWL
- •PCNL Access
- •Instrumentation for PCNL
- •Nephrostomy Drains Post PCNL
- •Contraindications to PCNL
- •Complications of PCNL
- •Semirigid Ureteroscopy
- •Flexible Ureteroscopy
- •Electrohydraulic Lithotripsy (EHL)
- •Ultrasound
- •Ballistic Lithotripsy
- •Laser Lithotripsy
- •Ureteric Stents
- •Staghorn Calculi
- •Lower Pole Stones
- •Horseshoe Kidneys and Stones
- •Calyceal Diverticula Stones
- •Stones and PUJ Obstruction
- •Treatment of Ureteric Colic
- •Medical Expulsive Therapy (MET)
- •Intervention for Ureteric Stones
- •Stones in Pregnancy
- •Morbid Obesity
- •References
- •Anatomy and Function
- •Pathophysiology
- •Management
- •Optical Urethrotomy/Dilatation
- •Urethral Stents
- •Preoperative Assessment
- •Urethroplasty
- •Anastomotic Urethroplasty
- •Substitution Urethroplasty
- •Grafts Versus Flaps
- •Oral Mucosal Grafts
- •Tissue Engineering
- •Graft Position
- •Conclusion
- •References
- •32: Urinary Incontinence
- •Epidemiology and Risk Factors
- •Pathophysiology
- •Urge Incontinence
- •Conservative Treatments
- •Pharmacotherapy
- •Invasive/ Surgical Therapies
- •Stress Urinary Incontinence
- •Male SUI Therapies
- •Female SUI Therapies
- •Mixed Urinary Incontinence
- •Conclusions
- •References
- •33: Neurogenic Bladder
- •Introduction
- •Examination and Diagnostic Tests
- •History and Physical Examination
- •Imaging
- •Urodynamics (UDS)
- •Evoked Potentials
- •Classifications
- •Somatic Pathways
- •Brain Lesions
- •Cerebrovascular Accident (CVA)
- •Parkinson’s Disease (PD)
- •Multiple Sclerosis
- •Huntington’s Disease
- •Dementias
- •Normal Pressure Hydrocephalus (NPH)
- •Tumors
- •Psychiatric Disorders
- •Spinal Lesions and Pathology
- •Intervertebral Disk Prolapse
- •Spinal Cord Injury (SCI)
- •Transverse Myelitis
- •Peripheral Neuropathies
- •Metabolic Neuropathies
- •Pelvic Surgery
- •Treatment
- •Summary
- •References
- •34: Pelvic Prolapse
- •Introduction
- •Epidemiology
- •Anatomy and Pathophysiology
- •Evaluation and Diagnosis
- •Outcome Measures
- •Imaging
- •Urodynamics
- •Indications for Management
- •Biosynthetics
- •Surgical Management
- •Anterior Compartment Repair
- •Uterine/Apical Prolapse
- •Enterocele Repair
- •Conclusion
- •References
- •35: Urinary Tract Fistula
- •Introduction
- •Urogynecologic Fistula
- •Vesicovaginal Fistula
- •Etiology and Risk Factors
- •Clinical Factors
- •Evaluation and Diagnosis
- •Pelvic Examination
- •Cystoscopy
- •Imaging
- •Treatment
- •Conservative Management
- •Surgical Management
- •Urethrovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Ureterovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Vesicouterine Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Uro-Enteric Fistula
- •Vesicoenteric Fistula
- •Pyeloenteric Fistula
- •Urethrorectal Fistula
- •References
- •36: Urologic Trauma
- •Introduction
- •Kidney
- •Expectant Management
- •Endovascular Therapy
- •Operative Intervention
- •Operative Management: Follow-up
- •Reno-Vascular Injuries
- •Pediatric Renal Injuries
- •Adrenal
- •Ureter
- •Diagnosis
- •Treatment
- •Delayed Diagnosis
- •Bladder and Posterior Urethra
- •Bladder Injuries: Initial Management
- •Bladder Injuries: Formal Repair
- •Anterior Urethral Trauma
- •Fractured Penis
- •Penile Amputation
- •Scrotal and Testicular Trauma
- •Imaging
- •CT-IVP (CT with Delayed Images)
- •Technique
- •Cystogram
- •Technique
- •Retrograde Urethrogram (RUG)
- •Technique
- •Retrograde Pyelogram (RPG)
- •Technique
- •One-Shot IVP
- •Technique
- •References
- •37: Bladder Cancer
- •Who Should Be Investigated?
- •Epidemiology
- •Risk Factors
- •Role of Screening
- •Signs and Symptoms
- •Imaging
- •Cystoscopy
- •Urine Tests
- •PDD-Assisted TUR
- •Pathology
- •NMIBC and Risk Groups
- •Intravesical Chemotherapy
- •Intravesical Immunotherapy
- •Immediate Cystectomy and CIS
- •Radical Cystectomy with Pelvic Lymph Node Dissection
- •sexual function-preserving techniques
- •Bladder-Preservation Treatments
- •Neoadjuvant Chemotherapy
- •Adjuvant Chemotherapy
- •Preoperative Radiotherapy
- •Follow-up After TUR in NMIBC
- •References
- •38: Prostate Cancer
- •Introduction
- •Epidemiology
- •Race
- •Geographic Variation
- •Risk Factors and Prevention
- •Family History
- •Diet and Lifestyle
- •Prevention
- •Screening and Diagnosis
- •Current Screening Recommendations
- •Biopsy
- •Pathology
- •Prognosis
- •Treatment of Prostate Cancer
- •Treatment for Localized Prostate Cancer (T1, T2)
- •Radical Prostatectomy
- •EBRT
- •IMRT
- •Brachytherapy
- •Treatment for Locally Advanced Prostate Cancer (T3, T4)
- •EBRT with ADT
- •Radical Prostatectomy
- •Androgen-Deprivation Therapy
- •Summary
- •References
- •39: The Management of Testis Cancer
- •Presentation and Diagnosis
- •Serum Tumor Markers
- •Primary Surgery
- •Testis Preserving Surgery
- •Risk Stratification
- •Surveillance Versus Primary RPLND
- •Primary RPLND
- •Adjuvant Treatment for High Risk
- •Clinical Stage 1 Seminoma
- •Risk-Stratified Adjuvant Treatment
- •Adjuvant Radiotherapy
- •Adjuvant Low Dose Chemotherapy
- •Primary Combination Chemotherapy
- •Late Toxicity
- •Salvage Strategies
- •Conclusion
- •References
- •Index
|
|
|
|
|
448 |
|
|
|
|
|
|
||
|
|
|
|
PRaCtiCal URology: ESSEntial PRinCiPlES and PRaCtiCE |
||
obstructive than the MMK83 and is usually the |
strategy is necessary. Conservative, pharmaco- |
|||||
colposuspension method of choice. Compli- |
logical, or surgical measures should bring about |
|||||
cations associated with the Burch include void- |
an improvement in quality of life and reduction |
|||||
ing difficulties, de novo detrusor overactivity, |
in incontinence episodes. |
|||||
and prolapse.92 Paravaginal repairs are reserved |
|
|
||||
for re-approximating the paravaginal fascia to |
References |
|||||
the pelvic sidewall at the level of the tendinous |
||||||
arc when there is detachment of the endopelvic |
|
|
||||
fascia.83 |
|
|
1. |
Hunskaar S, Arnold EP, Burgio K, et al. Epidemiology |
||
|
|
|
|
|
and natural history of urinary incontinence. Int |
|
|
|
|
|
|
Urogynecol J Pelvic Floor Dysfunct. 2000;11:301 |
|
Mixed Urinary Incontinence |
2. |
Wein AJ, Rackley RR. Overactive bladder: a better under- |
||||
|
standing of pathophysiology, diagnosis and manage- |
|||||
|
|
|
|
|
ment. J Urol. 2006;175:S5 |
|
The International Continence Society describes |
3. |
Abrams P, Cardozo L, Fall M, et al. The standardisation |
||||
|
of terminology in lower urinary tract function: report |
|||||
MUI as the complaint of involuntary leakage |
|
|||||
|
from the standardisation sub-committee of the Inter- |
|||||
associated with urgency and also with exertion, |
|
|||||
|
national Continence Society. Urology. 2003;61:37 |
|||||
effort, sneezing, or coughing.3 MUI is often |
4. |
Athanasopoulos A, Perimenis P. Pharmacotherapy of |
||||
treated as part of the treatment of SUI and UUI. |
|
urinary incontinence. Int Urogynecol J Pelvic Floor |
||||
This approach should be individualized,depend- |
5. |
Dysfunct. 2008;20(4):475-482 |
||||
ing on the severity of each component. Epide- |
Burt VL, Whelton P, Roccella EJ, et al. Prevalence of |
|||||
|
hypertension in the US adult population. Results from |
|||||
miological studies have shown that women with |
|
|||||
|
the third national health and nutrition examination sur- |
|||||
MUI symptoms typically have worse inconti- |
|
|||||
|
vey, 1988–1991. Hypertension. 1995;25:305 |
|||||
nence than women with a pure subtype.9 Dooley |
6. |
Silverstein B. Gender difference in the prevalence of |
||||
et al. compared the bother of MUI versus pure |
|
clinical depression: the role played by depression associ- |
||||
incontinence subtypes in 551 women. The |
|
ated with somatic symptoms. Am J Psychiatry. 1999; |
||||
Urinary Distress Inventory (UDI-6) scores were |
7. |
156:480 |
||||
significantly higher in women with MUI than |
Wild S, Roglic G, Green A, et al. Global prevalence of dia- |
|||||
|
betes: estimates for the year 2000 and projections for |
|||||
those with pure SUI or pure UUI.99 The urgency |
|
|||||
|
2030. Diab Care. 2004;27:1047 |
|||||
component is frequently more bothersome and |
|
|||||
8. |
Odeyemi IA, Dakin HA, O’Donnell RA, et al. |
|||||
treatment is thus initially focused on this aspect.4 |
|
Epidemiology, prescribing patterns and resource use |
||||
The efficacy of antimuscarinics in treatment of |
|
associated with overactive bladder in UK primary care. |
||||
MUI was studied. Seventy-six percent of patients |
9. |
Int J Clin Pract. 2006;60:949 |
||||
treated with 8 weeks of an antimuscarinic for |
Hannestad YS, Rortveit G, Sandvik H, et al. A commu- |
|||||
|
nity-based epidemiological survey of female urinary |
|||||
urgency(predominantlyMUI)reportedimprove- |
|
|||||
|
incontinence: the Norwegian EPINCONT study. Epi- |
|||||
ments as compared to a placebo group.100 |
|
|||||
|
demiology of incontinence in the county of nord- |
|||||
|
|
|
|
|
trondelag. J Clin Epidemiol. 2000;53:1150 |
|
|
|
|
|
10. |
Hunskaar S, Burgio K, Diokno AC, et al. Epidemiology |
|
Conclusions |
|
|
and natural history of urinary incontinence.In: Abrams P, |
|||
|
|
Cardozo L, Khoury S, WEin A, eds. Incontinence. 2nd ed. |
||||
|
|
|
|
|
Plymouth, UK: Health Publication Ltd.; 2002:165 |
|
Urinary incontinence carries a greater health, |
11. |
Tennstedt SL, Link CL, Steers WD, et al. Prevalence of |
||||
economic, and quality of life burden than most |
|
and risk factors for urine leakage in a racially and ethni- |
||||
chronic diseases. Aging and female gender are |
|
cally diverse population of adults: the Boston Area |
||||
|
Community Health (BACH) survey. Am J Epidemiol. |
|||||
two of the leading risk factors accounting for the |
|
|||||
|
2008;167:390 |
|||||
large numbers of incontinent individuals.Prompt |
|
|||||
12. |
Wilson MM. Urinary incontinence: selected current |
|||||
screening, assessment, and treatment for man- |
|
concepts. Med Clin North Am. 2006;90:825 |
||||
agement of UI will prevent avoidable morbidity |
13. |
Klauser A, Frauscher F, Strasser H, et al. Age-related |
||||
and mortality. To effectively treat UI in clinical |
|
rhabdosphincter function in female urinary stress |
||||
practice, it |
is advantageous |
to differentiate |
|
incontinence: assessment of intraurethral sonography. |
||
between SUI and UUI. Whether it is UI due to an |
|
J Ultrasound Med. 2004;23:631 |
||||
14. |
Lluel P, Deplanne V, Heudes D, et al. Age-related changes |
|||||
overactive |
detrusor, intrinsic |
sphincter defi- |
||||
|
in urethrovesical coordination in male rats: relationship |
|||||
ciency, urethral hypermobility, or functional lim- |
|
|||||
|
with bladder instability? Am J Physiol Regul Integr Comp |
|||||
itations, a dynamic, comprehensive management |
|
Physiol. 2003;284:R1287 |
||||
449
URinaRy inContinEnCE
15.Patel MD, Coshall C, Rudd AG, et al. Cognitive impairment after stroke: clinical determinants and its associations with long-term stroke outcomes. J Am Geriatr Soc. 2002;50:700
16.Yoshida M, Miyamae K, Iwashita H, et al. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology. 2004;63:17
17.Klausner AP, Vapnek JM. Urinary incontinence in the geriatric population. Mt Sinai J Med. 2003;70:54
18.Landi F, Cesari M, Russo A, et al. Potentially reversible risk factors and urinary incontinence in frail older people living in community. Age Ageing. 2003;32:194
19.McLoughlin MA, Chew DJ. Diagnosis and surgical management of ectopic ureters. Clin Tech Small Anim Pract. 2000;15:17
20.Ouslander JG. Intractable incontinence in the elderly. BJU Int. 2000;85(3):72
21.Zunzunegui Pastor MV, Rodriguez-Laso A, Garcia Yebenes MJ, et al. Prevalence of urinary incontinence and linked factors in men and women over 65. Aten Primaria. 2003;32:337
22.Bradway C. Urinary incontinence among older women. Measurement of the effect on health-related quality of life. J Gerontol Nurs. 2003;29:13
23.Hogan DB. Revisiting the O complex: urinary incontinence, delirium and polypharmacy in elderly patients. CMAJ. 1997;157:1071
24.Johansson C, Hellstrom L, Ekelund P, et al. Urinary incontinence: a minor risk factor for hip fractures in elderly women. Maturitas. 1996;25:21
25.Saltvedt I, Mo ES, Fayers P, et al. Reduced mortality in treating acutely sick, frail older patients in a geriatric evaluation and management unit. A prospective randomized trial. J Am Geriatr Soc. 2002;50:792
26.Baztan JJ, Arias E, Gonzalez N, et al. New-onset urinary incontinence and rehabilitation outcomes in frail older patients. Age Ageing. 2005;34:172
27.Miner PB Jr. Economic and personal impact of fecal and urinary incontinence. Gastroenterology. 2004;126:S8
28.Brading AF. A myogenic basis for the overactive bladder. Urology. 1997;50:57
29.Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J Urol. 1993;150:1668
30.Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction.IV.Bladder outlet obstruction. J Urol. 1993;150:1681
31.de Groat WC. A neurologic basis for the overactive bladder. Urology. 1997;50:36
32.Drake MJ, Mills IW, Gillespie JI. Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet. 2001; 358:401
33.Andersson KE,Appell R, Cardozo LD, et al. The pharmacological treatment of urinary incontinence. BJU Int. 1999;84:923
34.Hashim H, Abrams P. Overactive bladder: an update.
Curr Opin Urol. 2007;17:231
35.Andersson KE, Pehrson R. CNS involvement in overactive bladder. Drugs. 2003;63:2595
36.Cardozo L. New developments in the management of stress urinary incontinence. BJU Int. 2004;94(1):1
37.Mostwin JL. Urinary incontinence. J Urol. 1995;153:352
38.Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol. 1994;152:1831
39.Leach GE,Trockman B,Wong A,et al.Post-prostatectomy incontinence: urodynamic findings and treatment outcomes. J Urol. 1996;155:1256
40.Groutz A, Blaivas JG, Chaikin DC, et al. The pathophysiology of post-radical prostatectomy incontinence: a clinical and video urodynamic study. J Urol. 2000;163:1767
41.Coyne KS,Margolis MK,Thompson C,et al.Psychometric equivalence of the OAB-q in Danish, German, Polish, Swedish and Turkish. Int Soc Pharmacoeconomics Outcomes Res ISPOR. 2008;11(7):1096
42.Brown JS, McNaughton KS, Wyman JF, et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology. 2003; 61:802
43.Ku JH, Jeong IG, Lim DJ, et al.Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms: prospective assessment of patient compliance and burden. Neurourol Urodyn. 2004;23:331
44.Nygaard I, Holcomb R. Reproducibility of the seven-day voiding diary in women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11:15
45.Fletcher SG, Lemack GE. Clarifying the role of urodynamics in the preoperative evaluation of stress urinary incontinence. ScientificWorld J. 2008;8:1259
46.Patel AK, Chapple CR. Urodynamics in the management of female stress incontinence – which test and when?
Curr Opin Urol. 2008;18:359
47.Lemack GE, Xu Y, Brubaker L, et al. Clinical and demographic factors associated with valsalva leak point pressure among women undergoing burch bladder neck suspension or autologous rectus fascial sling procedures.
Neurourol Urodyn. 2007;26:392
48.Comiter CV. Surgery Insight: surgical management of postprostatectomy incontinence – the artificial urinary sphincter and male sling. Nat Clin Pract Urol. 2007; 4:615
49.Nager CW, FitzGerald M, Kraus SR, et al. Urodynamic measures do not predict stress continence outcomes after surgery for stress urinary incontinence in selected women. J Urol. 2008;179:1470
50.Paick JS, Oh SJ, Kim SW, et al. Tension-free vaginal tape, suprapubic arc sling, and transobturator tape in the treatment of mixed urinary incontinence in women. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:123
51.Burgio KL. Current perspectives on management of urgency using bladder and behavioral training. J Am Acad Nurse Pract. 2004;16:4
52.Andersson KE.Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46
53.Anderson RU, MacDiarmid S, Kell S, et al. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2006; 17:502
450
PRaCtiCal URology: ESSEntial PRinCiPlES and PRaCtiCE
54.Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur Urol. 2005;48:464
55.Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004;45:420
56.Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol. 1999;162:3
57.Holzer-Petsche U, Lembeck F. Systemic capsaicin treatment impairs the micturition reflex in the rat. Br J Pharmacol. 1984;83:935
58.Kawatani M, Whitney T, Booth AM, et al. Excitatory effect of substance P in parasympathetic ganglia of cat urinary bladder. Am J Physiol. 1989;257:R1450
59.Yoshimura N, Erdman SL, Snider MW, et al. Effects of spinal cord injury on neurofilament immunoreactivity and capsaicin sensitivity in rat dorsal root ganglion neurons innervating the urinary bladder. Neuroscience. 1998;83:633
60.Fowler CJ, Beck RO, Gerrard S, et al. Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry. 1994;57:169
61.Kim JH, Rivas DA, Shenot PJ, et al. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial.
J Spinal Cord Med. 2003;26:358
62.Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005; 174:977
63.Dmochowski R, Sand PK. Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int. 2007;99:247
64.Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum a injection. J Urol. 2008;180:217
65.van Kerrebroeck PEV, van Voskuilen AC, Heesakkers JPFA, Nijholt AABL, Siegel S, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of prospective,worldwide clinical study.J Urol. 2007;178:2029
66.Sutherland SE, Lavers A, Carlson A, Holtz C, Kesha J, Siegel SW. Sacral nerve stimulation for voiding dysfunction: one institution’s 11-year experience. Neurourol Urodyn. 2007;26:19
67.Cooperberg MR, Stoller ML. Posterior tibial nerve stimulation for pelvic floor dysfunction. In: Raz S, Larissa V, eds. Female Urology. 3rd ed. Philadelphia, PA: Saunders Elsevier; 2008
68.Parekh AR, Feng MI, Kirages D, Bremner H, et al. The role of pelvic floor exercises on post-prostatectomy incontinence. J Urol. 2003;170:130
69.Tiguert R et al. Collagen injection in the management of post-radical retropubic prostatectomy intrinsic sphincteric deficiency. Neurourol Urodyn. 1999;18:653
70.Smith DN et al. Collagen injection therapy for postprostatectomy incontinence. J Urol. 1998;160:364
71.Sanchez-Ortiz RF et al. Collagen injection therapy for post-radical retropubic prostatectomy incontinence: role of valsalva leak point pressure. J Urol. 1997; 158:2132
72.Comiter CV. Surgery insight: surgical management of postprostatecotmy incontinencethe artificial urinary sphincter and male sling. Nature. 2007;4:615
73.Montague DK, Angermeier KW. Postprostatectomy urinary incontinence: the case for artificial urinary sphincter implantation. Urology. 2000;55:2
74.Litwiller SE et al. Post-prostatectomy iIncontinence and the artificial urinary sphincter: a long-term study of patient satisfaction and criteria for success. J Urol. 1996;156(6):1975-1980
75.Petrou SP et al. Artificial urinary sphincter for incontinence. Urology. 2000;56:353
76.Fulford SC et al. The fate of the “modern” artificial urinary sphincter with a follow-up of more than 10 Years. Br J Urol. 1997;79:713
77.Montague DK. The artificial urinary sphincter (AMS 800): experience in 166 consecutive patients. J Urol. 1992;147:380
78.Elliott DS, Barrett DM. May clinic long-term analysis of the functional durability of the AMS 800 artificial urinary sphincter: a review of the 323 cases. J Urol. 1998;159:1206
79.Comiter CV. The male perineal sling: intermediate-term results. Neurourol Urodyn. 2005;24:648
80.Rajpurkar AD et al. Patient satisfaction and clinical efficacy of the new perineal bone-anchored male sling. Eur Urol. 2005;47:237
81.Rehder P, Gozzi C. Transobturator sling suspension for male urinary incontinence including post-radical prostatectomy. Eur Urol. 2007;52:860
82.Pesce F. Current management of stress urinary incontinence. BJU Int. 2004;94:8
83.Rovner ES,Wein AJ. Treatment options for stress urinary incontinence. Rev Urol. 2004;6:S29
84.Wyman JF, Fantl JA, McClish DK, Bump RC. For the continenceprogramforwomenresearchgroup.Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Am J Obstet Gynecol. 1998;179:999
85.Wilson PD, Bo K, Hay-Smith J, et al. Conservative treatment in women. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. 2nd ed. Plymouth, UK: Health Publication Ltd.; 2002:571-624
86.Agency for Health Care Policy and Research, US Department of Health and Human Services. Clinical Practice Guidelines: Urinary Incontinence in Adults. Rockville, MD: Agency for Health Care Policy and Research; 1992. AHCPR Publication 92–0038
87.Lin HH, Sheu BC, Lo MC, Huang SC. Comparison of treatment outcomes for imipramine for female genuine stress incontinence. Br J Obstet Gynaecol. 1999; 106:1089
88.Basu M, Duckett J. The treatment of urinary incontinence with Duloxetine. J Obstet Gynaecol. 2008;28:166
451
URinaRy inContinEnCE
89.Vella M, Duckett J, Basu M. Duloxetine 1 year on: the long-term outcome of a cohort of women prescribed duloxetine. Int Urogynecol J. 2008;19:961
90.Yasuda K, Kawabe K, Takimoto Y, The Clenbuterol Clinical Research Group, et al. A double-blind clinical trial of a ß2-adrenergic agonist in stress incontinence.
Int Urogynecol J. 1993;4:146
91. Rogers RG. Urinary stress incontinence in women. N Engl J Med. 2008;358:1029-1036
92.Abrams P,Cardozo L,Khoury S,WeinA,eds.Incontinence. 2nd ed. Plymouth, UK: Health Publication Ltd.; 2002
93.Leach GE, Dmochowski RR, Appell RA, et al. Female stress urinary incontinence clinical guidelines panel summary report on surgical management of female stress urinary incontinence. J Urol. 1997;158:875
94.Ward KL, Hilton P. UK and Ireland TVT trial group. A prospective multicenter randomized trial of tensionfree vaginal tape and colposuspension for primary urodynamic stress incontinence: 2-year follow-up. Am J Obstet Gynecol. 2004;190:324
95.Wang W, Zhu L, Lang J. Transobturator tape procedure versus tension-free vaginal tape for treatment of stress urinary incontinence.Int J Gynaecol Obstet.2009;104(2): 113-116
96.Schulz JA, Chan MC, Farrell SA. The sub-committee on urogynaecology. Midurethral minimally invasive sling procedures for stress. Urin Incontin. 2008;213:728
97.Molden SM, Lucente VR. New minimally invasive slings: TVT Secur. Curr Urol Rep. 2008;9:358
98.Zimmern PE, Hadley HR, Leach GE, et al. Female urethral obstruction after Marshall-Marchetti-Krantz operation. J Urol. 1987;138:517
99.Dooley Y, Lowenstein L, Kenton K, et al. Mixed incontinence is more bother than pure incontinence subtypes.
Int Urogynecol J. 2008;19:1359
100.Khullar V, Hill S, Laval KU, Schiotz HA, et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebocontrolled trial. Urology. 2004;64:269